pyrazines has been researched along with Rhabdomyosarcoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonvini, P; Peron, M; Rosolen, A | 1 |
| Accornero, P; Bersani, F; Crepaldi, T; Miretti, S; Morotti, A; Ponzetto, C; Taulli, R | 1 |
| Brodfüehrer, JI; Melder, DC; Moore, DJ; Powis, G; Wilke, TJ | 1 |
3 other study(ies) available for pyrazines and Rhabdomyosarcoma
| Article | Year |
|---|---|
Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of rhabdomyosarcoma cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Benzoquinones; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Cell Survival; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Proteasome Endopeptidase Complex; Pyrazines; Rhabdomyosarcoma; Ubiquitin | 2012 |
Bortezomib-mediated proteasome inhibition as a potential strategy for the treatment of rhabdomyosarcoma.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Survival; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Rhabdomyosarcoma; Transplantation, Heterologous; Tumor Cells, Cultured | 2008 |
In vitro cytotoxicity of pyrazine-2-diazohydroxide: specificity for hypoxic cells and effects of microsomal coincubation.
Topics: Animals; Antineoplastic Agents; Cell Survival; Half-Life; Humans; Hydrogen-Ion Concentration; Male; Microsomes, Liver; Pyrazines; Rats; Rats, Inbred F344; Rhabdomyosarcoma; Sulfhydryl Compounds; Tumor Cells, Cultured | 1988 |